Your session is about to expire
← Back to Search
TMB-365 + TMB-380 for HIV
Study Summary
This trial is testing a combination of two antibodies, TMB-365 and TMB-380, for safety and how well they work in people with HIV who are already taking other medication.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use birth control and undergo pregnancy tests if I can still have children.I am between 18 and 60 years old.I agree to use birth control and undergo pregnancy tests if I can still have children.I have not received monoclonal antibodies for HIV except as a Sentinel subject.I haven't taken immune system drugs, HIV vaccines, chemotherapy, or experimental treatments in the last 6 months.I have been on consistent HIV treatment for 6 months with an undetectable viral load in the last 3 months.I have HIV but do not show symptoms, confirmed by tests.I am on maintenance therapy for HIV with cabotegravir and rilpivirine injections.You have a high hemoglobin level.I have been on a stable HIV treatment for less than 3 months.I have been on consistent HIV treatment for 6 months with an undetectable viral load in the last 3 months.I do not have a history of severe mental health issues like schizophrenia, uncontrolled bipolar disorder, or recent suicide attempts.I have had HIV treatment fail twice or more, but not just due to intolerance.I have been on consistent HIV treatment for 6 months with an undetectable viral load in the last 3 months.I have difficulty with IV lines due to poor vein access.I have HIV but do not show symptoms, confirmed by tests.I am between 18 and 60 years old.I haven't been hospitalized or needed treatment for a serious illness in the last 3 weeks.You have a positive test result for HIV-1 RNA.I am between 18 and 60 years old.I have HIV but do not show symptoms, confirmed by tests.
- Group 1: Core Group 1
- Group 2: Sentinel Group 1
- Group 3: Sentinel Group 2
- Group 4: Sentinel Group 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the participant count for this research project?
"The total number of participants necessary to pursue the trial is 90, which TaiMed Biologics Inc. will be sourcing from Quest Clinical Research (San Francisco) and Gary Richmond MD PA (Fort Lauderdale)."
Is this research endeavor presently recruiting participants?
"Affirmative. According to the details hosted on clinicaltrials.gov, this trial is actively recruitting participants since its launch date of July 5th 2022 and presently enrolling 90 patients from 6 different locations. The data was last updated on October 25th 2022."
What is the prevalence of this medical experiment in city?
"The current roster of participating medical centres consists of Quest Clinical Research in San Francisco, Gary Richmond MD PA in Fort Lauderdale, and Crofoot Research Center Inc. in Houston, alongside 6 other locations."
Could individuals younger than 55 years old meet the requirements of this experiment?
"This trial has set the age limit for applicants to be between 18 and 60 years old. Any patients below 18 or above 65 can join one of the other 94 clinical trials that are relevant to their situation."
What qualifications must participants meet in order to partake in this trial?
"The criteria for joining this medical study necessitates that participants possess HIV-1, stand between 18 and 60 years of age, with the total number of recruiters expected to be approximately 90."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Average response time
- < 1 Day
Most responsive sites:
- Crofoot Research Center, Inc.: < 24 hours
Share this study with friends
Copy Link
Messenger